- Home
- BJRI vs LXRX Comparison
BJRI vs LXRX Comparison
Compare BJRI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | LXRX |
|---|---|---|
| Founded | 1978 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.4M | 660.9M |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BJRI | LXRX |
|---|---|---|
| Price | $37.68 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $42.88 | $4.15 |
| AVG Volume (30 Days) | 267.4K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 77.78 |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $3.89 | N/A |
| P/E Ratio | $17.26 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $28.46 | $0.51 |
| 52 Week High | $47.02 | $1.95 |
Technical Indicators
Market Signals| Indicator | BJRI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 40.99 |
| Support Level | $33.60 | $1.47 |
| Resistance Level | $39.47 | $1.65 |
| Average True Range (ATR) | 1.24 | 0.10 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 37.43 | 6.25 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.